100–200 mg/day with a fatty meal.
In older men ubiquinol raises blood CoQ10 more than ubiquinone (the usual oxidized form in supplements): ×1.5 total CoQ10. But it did NOT change oxidative stress markers or ATP, and it is a very small study (n=10): better absorption does not equal proven clinical benefit.
View the study (trial (RCT)) →⏱ 3 min read
Ubiquinol is the reduced (active) form of coenzyme Q10 (also known as ubiquinone in its oxidized form), a molecule present in practically all cells of the body where it performs two essential functions: it is the electron carrier between complexes I/II and III of the mitochondrial respiratory chain (indispensable for ATP production) and it acts as a potent lipophilic antioxidant that protects cell membranes and plasma lipoproteins from lipid peroxidation; in the body, about 95 percent of circulating CoQ10 in healthy people is in its reduced form, ubiquinol, a proportion that declines with age and in several pathologies.
Unlike conventional ubiquinone (the oldest and cheapest commercial form of CoQ10 as a supplement), ubiquinol has significantly higher oral bioavailability, especially in people over 50, in people with impaired liver or intestinal function, and in people with problems reducing ubiquinone to its active form; this pharmacokinetic difference is the main justification for the higher cost of ubiquinol compared with ubiquinone, although the magnitude of the real clinical difference in healthy young people is probably modest.
Conventional ubiquinone is the most clinically studied option, more economical, and effective for most people with normal absorptive and enzymatic function; ubiquinol justifies its higher cost in people over 50 (where the endogenous conversion of ubiquinone to ubiquinol may be reduced), in people with compromised liver function, in people with serious digestive problems, in elite athletes seeking maximum bioavailability, and in patients with severe mitochondrial disorders where maximizing the availability of the active form may be clinically relevant.
For more detail on coenzyme Q10 in general (mechanisms, main indications in heart failure, migraine prophylaxis, fertility, and others), see the specific coenzyme Q10 profile in this database; this article focuses specifically on the differential considerations of ubiquinol as a formulation.
In heart failure, especially in older adults and in advanced stages where mitochondrial dysfunction is an important component of the condition, ubiquinol at doses of 200-300 mg/day has shown, in small studies, significant improvements in ejection fraction, exercise capacity, and cardiac biomarkers compared with placebo, an indication consistent with the mechanistic basis and with interesting preliminary clinical data.
In chronic fatigue syndrome, fibromyalgia, and other conditions with a postulated mitochondrial component, ubiquinol may provide benefits when the endogenous conversion of ubiquinone to ubiquinol is compromised; the specific clinical data in these conditions are preliminary but consistent with the mechanistic profile.
Statins significantly reduce plasma CoQ10 concentrations through inhibition of HMG-CoA reductase (the enzyme also required for endogenous CoQ10 synthesis); in people with statin-associated muscle adverse effects (myalgia, cramps, weakness), supplementation with ubiquinol or ubiquinone may provide symptomatic improvement, an indication with modest clinical support but a clear mechanistic basis and reasonable integrative use.
The doses studied for ubiquinol range from 50 to 300 milligrams per day depending on the indication, divided into one or two doses taken with a fatty meal to optimize absorption (both ubiquinol and ubiquinone are lipophilic); for general indications (mitochondrial support, anti-aging), 100-200 mg/day; for heart failure or specific mitochondrial conditions, 200-300 mg/day in divided doses; typical commercial products contain 50-200 mg of ubiquinol per capsule; oil-based encapsulated formulations (softgels) are significantly more bioavailable than dry powders.
Generally very well tolerated at the doses studied; the adverse effects described are rare and mild (mild digestive discomfort, occasionally headache or insomnia if taken too late in the day); people taking warfarin should monitor their INR because ubiquinol/CoQ10 may reduce the anticoagulant effect of warfarin with clinically relevant potency; those taking antihypertensives may experience a mild potentiation of the blood-pressure-lowering effect; in pregnancy and breastfeeding, specific data are limited and avoiding high doses as a precaution is recommended; people with cancers that depend on specific mitochondrial pathways should exercise theoretical caution; the cost per milligram of ubiquinol is significantly higher than that of conventional ubiquinone, and the choice between the two forms should be weighed according to the individual characteristics of the user (age, absorptive function, specific conditions); for young, healthy people with normal absorptive function, conventional ubiquinone is probably more efficient in terms of cost-benefit; for adults over 50 or people with the specific conditions discussed, ubiquinol may justify the higher cost.
Information, not medical advice. Scientific evidence reflects the quality of the studies.